B-cells in stroke-associated infection

  • Research type

    Research Study

  • Full title

    Understanding stroke-induced B cell changes and their relationships with stroke-associated infection

  • IRAS ID

    237040

  • Contact name

    Craig Smith

  • Contact email

    craig.smith-2@manchester.ac.uk

  • Sponsor organisation

    Salford Royal NHS Foundation Trust

  • Duration of Study in the UK

    2 years, 3 months, 31 days

  • Research summary

    Summary of Research
    Why - The study will examine the affect that stroke has on the body’s immune system. The most frequent complication of stroke that reduces the chances of a good recovery is infection, particularly from bacteria causing pneumonia in the lungs, which normally occurs in the first few days after stroke. At the moment, there are no treatments that are effective at reducing stroke-associated infection.

    What – A blood sample will be obtained from stroke patients between 24-48h hours of admission to hospital to measurement of levels of b-cells (type of immune cell in the blood) and to observe how stroke changes their function. Further assessments will be performed at 7days from stroke onset to record infection and antibiotic therapy and at 3month to assess functional recovery (modified Rankin Scale).

    Who - The study will recruit patients who have suffered a stroke, caused either by a blocked artery (ischaemic) or a bleed (intracerebral haemorrhage) and who have difficulty with swallowing putting them at a higher risk of pneumonia. In addition, a single blood sample will be obtained from people with no history of stroke (controls).

    Where/How –Participants will be recruited from Salford Royal NHS Foundation Trust beginning on 1st July, 2018 with follow-up completed by 3oth June, 2020. Recruitment of non-stroke volunteers and analysis of data will be completed no later than 31st October, 2020.

    Summary of Research
    In this research study we showed that following acute ischaemic stroke, the abundance and function
    of marginal zone (MZ)-like B cells, a subset of B cells in the blood, are markedly reduced. Release of
    antibodies (immunoglobulin (Ig) M), a key factor important in anti-bacterial responses, and other
    inflammatory molecules, from these cells were impaired. Lower MZ-like B cell frequencies were
    associated with mortality and dependence at 3 months, but not when severity of stroke was taken
    into account. Reduction of MZ-like B cell numbers was not associated with development of infection.
    Taken together, these findings demonstrate stroke rapidly alters specific subsets of blood B cells and
    highlight altered innate-like B cell function as an important feature of the immunological response to
    acute stroke.
    Dissemination, outputs and impact:
    Findings from this research has been presented at several scientific meetings including Stroke
    Immunology, British Society of Immunology and European Stroke Organisation Conference. Work
    from this study formed part of a successful PhD thesis. The main research paper that describes the
    full results of the study is currently under review in Journal of Clinical Investigation Insights.
    Patient and public involvement:
    We have disseminated the main findings of the study to our local PPIE group.
    Conclusions and future plans:
    This project, along with companion studies in experimental stroke has found that certain B cell
    subsets are significantly altered after a stroke, with reduction of the numbers and functionality
    (including reduced antibody production) of subsets that are important in defence against infections.
    Although we did not find a definite link between MZ-like B cells and development of infection, this
    remains a possibility which we think requires further study. Plans are currently in place to evaluate
    immunoglobulin therapy as a means of helping to prevent stroke-associated infections, initially in
    experimental stroke.

    Summary of Results
    In this research study we showed that following acute ischaemic stroke, the abundance and function of marginal zone (MZ)-like B cells, a subset of B cells in the blood, are markedly reduced. Release of antibodies (immunoglobulin (Ig) M), a key factor important in anti-bacterial responses, and other inflammatory molecules, from these cells were impaired. Lower MZ-like B cell frequencies were associated with mortality and dependence at 3 months, but not when severity of stroke was taken into account. Reduction of MZ-like B cell numbers was not associated with development of infection.
    Taken together, these findings demonstrate stroke rapidly alters specific subsets of blood B cells and highlight altered innate-like B cell function as an important feature of the immunological response to acute stroke.

    This project, along with companion studies in experimental stroke has found that certain B cell subsets are significantly altered after a stroke, with reduction of the numbers and functionality (including reduced antibody production) of subsets that are important in defence against infections. Although we did not find a definite link between MZ-like B cells and development of infection, this remains a possibility which we think requires further study. Plans are currently in place to evaluate immunoglobulin therapy as a means of helping to prevent stroke-associated infections, initially in experimental stroke.

  • REC name

    North West - Greater Manchester South Research Ethics Committee

  • REC reference

    18/NW/0415

  • Date of REC Opinion

    2 Jul 2018

  • REC opinion

    Favourable Opinion